Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma

Lead Sponsor

Northwell Health

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•18 years of age or older.
•Documented histologic diagnosis of relapsed or refractory glioblastoma multiforme (GBM), anaplastic astrocytoma (AA) or anaplastic mixed oligoastrocytoma (AOA).
•Circumscribed tumor recurrence with less than 3.5 cm greatest diameter
•Patients with histologically confirmed low-grade brain tumor relapse with an enhancing tumor on MRI will be evaluated for toxicity only.
•Patients must have at least one confirmed and evaluable tumor site.
•Patients must have a Karnofsky performance status 70% (or the equivalent ECOG level of 0-2)
•Patients must agree to use a medically effective method of contraception during and for a period of three months after the treatment period.

•Women who are pregnant or lactating.
•Patients with significant intercurrent medical or psychiatric conditions that would place them at increased risk or affect their ability to receive or comply with treatment or post-treatment clinical monitoring.
•Low GFR or history of hepatorenal syndrome